<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">8105311</article-id><article-id pub-id-type="publisher-id">89144</article-id><article-id pub-id-type="doi">10.1038/s41598-021-89144-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>High loading of trimethylglycine promotes aqueous solubility of poorly water-soluble cisplatin</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kadokawa</surname><given-names>Riki</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Fujie</surname><given-names>Tetsuo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Gyanendra</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ishibashi</surname><given-names>Kojiro</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ninomiya</surname><given-names>Kazuaki</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Hirata</surname><given-names>Eishu</given-names></name><address><email>ehirata@staff.kanazawa-u.ac.jp</email></address><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Kuroda</surname><given-names>Kosuke</given-names></name><address><email>kkuroda@staff.kanazawa-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Faculty of Biological Science and Technology, Institute of Science and Engineering, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Japan </aff><aff id="Aff2"><label>2</label>Division of Tumor Cell Biology and Bioimaging, Cancer Research Institute of Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Japan </aff><aff id="Aff3"><label>3</label>Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Japan </aff><aff id="Aff4"><label>4</label>Nano Life Science Institute of Kanazawa University, Kakuma-machi, Kanazawa, 920-1192 Japan </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>5</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>11</volume><elocation-id>9770</elocation-id><history><date date-type="received"><day>16</day><month>2</month><year>2021</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2021</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2021</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Trimethylglycine (TMG) is a cheap, natural, and highly biocompatible compound. Therefore, it has been used in the fields of food and life sciences, but the application of solid TMG is limited to utilisation as an &#x0201c;additive&#x0201d;. In the present study, we focussed on the high solubility of TMG in water, derived from the aprotic zwitterionic structure, and proposed TMG as the chemical accounting for a major portion of the aqueous solution (e.g., 50 wt%). High loading of TMG shifted the properties of water and enabled the dissolution of poorly water-soluble cisplatin, an anticancer agent, at high concentration (solubility of cisplatin: 0.15 wt% in water <italic>vs</italic> 1.7 wt% in TMG aqueous solution). For hepatic arterial infusion, this can reduce the amount of cisplatin administered from 40 to 4&#x000a0;mL. It enables simple injection using a syringe, without the need for catheters and automatic pumps, leading to critical alleviation of the risk to patients. Furthermore, we produced a dry powder from a cisplatin-containing TMG aqueous solution via freeze-drying. Powders can be conveniently stored and transported. Furthermore, cisplatin is often used as a mixture with other drugs, and cisplatin aqueous solutions are not preferred as they dilute the other drugs.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Cancer</kwd><kwd>Drug discovery</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001691</institution-id><institution>Japan Society for the Promotion of Science</institution></institution-wrap></funding-source><award-id>KAKENHI</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Kanazawa University</institution></funding-source><award-id>SAKIGAKE project 2020</award-id><award-id>SAKIGAKE project 2020</award-id><principal-award-recipient><name><surname>Takahashi</surname><given-names>Kenji</given-names></name><name><surname>Hirata</surname><given-names>Eishu</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002241</institution-id><institution>Japan Science and Technology Agency</institution></institution-wrap></funding-source><award-id>ACT-X</award-id><principal-award-recipient><name><surname>Hirata</surname><given-names>Eishu</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Ministry of Education, Culture, Sports, Science and Technology-Japan</institution></funding-source><award-id>Leading Initiative for Excellent Young Researchers</award-id><principal-award-recipient><name><surname>Hirata</surname><given-names>Eishu</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Trimethylglycine (TMG) is present in various organisms and is especially rich in sugar beets. It is also the most commonly accumulated osmolyte in nature<sup><xref ref-type="bibr" rid="CR1">1</xref>&#x02013;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Therefore, TMG has been established as a low-price and highly biocompatible compound and used as an additive in food and cosmetic preparations. Furthermore, TMG has found application in life sciences as an additive, including as a polymerase chain reaction adjuvant<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> and cryoprotective agent<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>. In other words, TMG has been employed as an additive to exert its functions in water as TMG is solid.</p><p id="Par3">In the present study, we proposed the use of TMG to account for a major proportion of the aqueous solution (e.g., 50 wt%). TMG is a known natural aprotic zwitterion, presenting high water solubility owing to the charges, unlike most amino acids. High loading of TMG can drastically alter the nature of water, adding properties to water that cannot be realised by pure water or dilute aqueous solutions. Accordingly, the dissolution of poorly water-soluble drugs is a good candidate for these properties owing to the biocompatibility of TMG. Typically, the dissolution of poorly water-soluble drugs is achieved using organic solvents such as dimethyl sulfoxide (DMSO)<sup><xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref></sup>. However, organic solvents, including DMSO, are toxic and should be avoided in clinical and fundamental researches if possible<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par4">We employed a 50 wt% TMG aqueous solution (aq.) as a nearly saturated solution. In the present study, we used cisplatin as the poorly water-soluble platinum agent. Although cisplatin is a classical anticancer agent, it is used to treat certain cancer types such as triple-negative breast cancer. Dissolution of cisplatin in DMSO is especially avoided because chloride, as a ligand of cisplatin, is exchanged for DMSO, with the anticancer effect of cisplatin finally abolished<sup><xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR15">15</xref></sup>. Thus, we proposed a 50 wt% TMG aq. as an efficient cisplatin solvent without eliminating its anticancer effect.</p></sec><sec id="Sec2"><title>Results and discussion</title><p id="Par5">Cisplatin is poorly water-soluble, with marginal solubility (approximately 0.15 wt%<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>). The 50 wt% TMG aq. dissolved 1.7 wt% of cisplatin (Table <xref rid="Tab1" ref-type="table">1</xref>). The diluted TMG solutions (25 and 5 wt%) dissolved less than 1.0 wt% of cisplatin, indicating that high loading of TMG is required to functionalise and dissolve cisplatin. High loading of L-carnitine, an analogous natural aprotic zwitterion, with a solubility of approximately 70 wt% in water, functionalised water, and the concentrated L-carnitine aq. dissolved cisplatin (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Solubility of cisplatin in TMG or L-carnitine aqs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Content (wt%)</th><th align="left">Solubility of cisplatin (wt%)<break/>
<inline-graphic xlink:href="41598_2021_89144_Figa_HTML.gif" id="d32e380"/></th></tr></thead><tbody><tr><td align="left" rowspan="3"><p>TMG</p><p>
<inline-graphic xlink:href="41598_2021_89144_Figb_HTML.gif" id="d32e389"/></p></td><td align="left">50</td><td char="." align="char">1.7</td></tr><tr><td align="left">25</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;1.0</td></tr><tr><td align="left">5</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;1.0</td></tr><tr><td align="left" rowspan="4"><p>L-carnitine</p><p>
<inline-graphic xlink:href="41598_2021_89144_Figc_HTML.gif" id="d32e417"/></p></td><td align="left">70</td><td char="." align="char">1.4</td></tr><tr><td align="left">50</td><td char="." align="char">1.0</td></tr><tr><td align="left">25</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;1.0</td></tr><tr><td align="left">5</td><td char="." align="char">&#x02009;&#x0003c;&#x02009;1.0</td></tr><tr><td align="left">Water<sup>a</sup></td><td align="left">&#x02013;</td><td char="." align="char">0.15<sup><xref ref-type="bibr" rid="CR16">16</xref></sup></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>150 mM NaCl aq. at ambient temperature. The same solubility is shown in phosphate-buffered saline.</p></table-wrap-foot></table-wrap></p><p id="Par6">The 50 wt% TMG aq. dissolved cisplatin at an 11 times higher concentration than phosphate-buffered saline (PBS). Accordingly, the cisplatin solution administered to patients can be reduced to one-eleventh. For hepatic arterial infusion of cisplatin, 40&#x02013;50&#x000a0;mL of a saturated cisplatin solution (0.15 wt%) is administered to a typical adult male using a catheter and an automatic pump. Theoretically, the highly concentrated cisplatin (1.7 wt%)/TMG solution reduces the amount to 4&#x02013;5&#x000a0;mL, allowing injection using a syringe, without the need for catheters and automatic pumps, resulting in the critical alleviation of patient risk.</p><p id="Par7">To discuss the dissolution mechanism of cisplatin in the TMG solution, the polarity of TMG was investigated. Ions have generally high polarity due to their positive- and negative charges. Since TMG does not have special functional groups, we considered the hydrogen bonding between TMG and cisplatin based on the high polarity should be a reason to solubilise. For solvents and organic ions, Kamlet-Taft parameters are generally used as indicators of the polarity<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>. In detail, <italic>&#x003b2;</italic> value in the parameters exhibits the hydrogen bond basicity and the calculated <italic>&#x003b2;</italic> value of TMG was 0.77. It is higher than that of water (around 0.15<sup><xref ref-type="bibr" rid="CR17">17</xref></sup>), which does not dissolve cisplatin, and similar to that of cisplatin-dissolving DMSO (0.83<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>). Therefore, the hydrogen bonding between carboxylate anion of TMG and ammonia&#x000a0;ligand is considered to be a key factor to dissolve.</p><p id="Par8">We confirmed that cisplatin dissolved in the 50 wt% TMG aq. retained its anticancer effects. The 50 wt% TMG aq. containing 10&#x000a0;mM cisplatin was prepared and added to human breast cancer cells (MDA-MB-231) at final concentrations ranging between 0.1 and 100&#x000a0;&#x000b5;M, by dilution in a culture medium. After incubation for 72&#x000a0;h, cell viability was measured and was decreased in a dose-dependent manner (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). On employing DMSO as the solvent, the anticancer effect of cisplatin was abolished, as previously reported<sup><xref ref-type="bibr" rid="CR10">10</xref></sup>. Furthermore, cisplatin dissolved in a 50 wt% L-carnitine aq. also&#x000a0;retained the anticancer effect.<fig id="Fig1"><label>Figure 1</label><caption><p>MDA-MB-231 cell viability after treatment with cisplatin dissolved in the indicated solvents. (n&#x02009;=&#x02009;3, biologically triplicated).</p></caption><graphic xlink:href="41598_2021_89144_Fig1_HTML" id="MO1"/></fig></p><p id="Par9">The ammonia ligand of cisplatin (Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>) is stable, but the chloride ligand is exchangeable in the TMG aq. The replacement species are presumed to be water- or carboxylate-containing TMG. Cisplatin in the 50 wt% TMG aq. was measured using <sup>195</sup>Pt NMR spectroscopy (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). K<sub>2</sub>[PtCl<sub>4</sub>] was used in H<sub>2</sub>O (&#x02212;&#x02009;1628&#x000a0;ppm; &#x02212;1.628 ppt in&#x000a0;Fig. <xref rid="Fig2" ref-type="fig">2</xref>)<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup> as a reference. A part of K<sub>2</sub>[PtCl<sub>4</sub>] was converted to K<sub>2</sub>[PtCl<sub>3</sub>(D<sub>2</sub>O)] in D<sub>2</sub>O, detected at &#x02212;&#x02009;1196&#x000a0;ppm. Immediately after dissolution, Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> was observed at&#x02009;&#x02212;&#x02009;2145 ppm<sup><xref ref-type="bibr" rid="CR21">21</xref></sup> in the 50&#x000a0;wt% TMG aq. The absence of other peaks suggests that ligand exchange did not occur. The solution was left at room temperature and evaluated on days 5 and 10. Although Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> was observed, another peak was observed at&#x02009;&#x02212;&#x02009;1821&#x000a0;ppm, indicating that the chloride ligand was exchanged. When the integral value of the signal of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> was fixed as 1.0, that of the emerging compound was 1.25 and 1.90 at days 5 and 10, respectively. The exchange proceeded over time, with 66&#x000a0;mol% of the chloride ligand exchanged after 10&#x000a0;days.<fig id="Fig2"><label>Figure 2</label><caption><p><sup>195</sup>Pt NMR spectra of cisplatin dissolved in 50 wt% TMG aq. Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>:&#x02009;&#x02212;&#x02009;2145&#x000a0;ppm, [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup>:&#x02009;&#x02212;&#x02009;1821&#x000a0;ppm. The x axis is shown in ppt.&#x000a0;We used co-axial tubes and K<sub>2</sub>[PtCl<sub>4</sub>] in D<sub>2</sub>O was in the inner tube.</p></caption><graphic xlink:href="41598_2021_89144_Fig2_HTML" id="MO2"/></fig></p><p id="Par10">The emerging signal at&#x02009;&#x02212;&#x02009;1821&#x000a0;ppm can be derived from either of the following compounds: [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(TMG)]<sup>+</sup>, [Pt(NH<sub>3</sub>)<sub>2</sub>(TMG)<sub>2</sub>]<sup>2+</sup>, [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup>, and [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup>. Herein, we performed mass spectrometry for the cisplatin-dissolved TMG aq.; however, none of them were detected owing to the extremely strong signal of excess TMG. Therefore, we measured cisplatin dissolved in water. Despite the low solubility (0.15 wt%), it is sufficient for performing mass spectrometry. A signal for [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> (m/z&#x02009;=&#x02009;282) and a slight signal for [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup> (m/z&#x02009;=&#x02009;133) were detected (Fig. <xref rid="MOESM1" ref-type="media">S1</xref>). Then, the same sample was subjected to <sup>195</sup>Pt NMR spectroscopy (370,000 scans due to low solubility). A signal appeared at&#x02009;&#x02212;&#x02009;1839&#x000a0;ppm, in addition to the signal for Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (&#x02212;&#x02009;2148&#x000a0;ppm) (Fig. <xref rid="MOESM1" ref-type="media"> S2</xref>). The new signal was assigned to [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup>, in accordance with the previous literature stating that signals for [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> and [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup> in water appear at approximately&#x02009;&#x02212;&#x02009;1841<sup><xref ref-type="bibr" rid="CR21">21</xref>,<xref ref-type="bibr" rid="CR22">22</xref></sup> and&#x02009;&#x02212;&#x02009;1567 ppm<sup><xref ref-type="bibr" rid="CR22">22</xref>,<xref ref-type="bibr" rid="CR23">23</xref></sup>, respectively. [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup> observed by mass spectrometry was not detected by <sup>195</sup>Pt NMR, presumably because of detection sensitivities and the low concentration of [Pt(NH<sub>3</sub>)<sub>2</sub>(H<sub>2</sub>O)<sub>2</sub>]<sup>2+</sup>.From these results, It was confirmed that chloride in cisplatin was exchanged not for TMG but for water in the 50 wt% TMG aq. after several days.</p><p id="Par11">[Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> should scarcely enter cells owing to their positive charges<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>. Conversely, the anticancer effect was maintained in the 50 wt% TMG aq., as shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. The ligand exchange between Cl<sup>&#x02013;</sup> and H<sub>2</sub>O is known to be an equilibrium reaction<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR26">26</xref></sup>, and Cl<sup>&#x02212;</sup>-rich solutions can cause ligand re-exchange from [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> to Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>. In the experiment shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>, the initial stock solution was prepared as 10&#x000a0;mM cisplatin dissolved in 50 wt% TMG aq., and then it was diluted to the desired concentrations with the medium before treating MDA-MB-231 cells. Hence, NaCl contained in the medium is assumed to induce ligand re-exchange even in the presence of TMG.</p><p id="Par12">Cisplatin was dissolved in 50 wt% TMG aq., and then left for 24&#x000a0;h. The ratios of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> and [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> were 83 and 17&#x000a0;mol%, respectively, as measured by <sup>195</sup>Pt NMR (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, day 1). Later, NaCl was additionally dissolved, and the ratio was evaluated on days 2&#x02013;4. As expected, [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> decreased: the ratios at days 2, 3, and 4 were 2, 0, and 0&#x000a0;mol%, respectively. Therefore, [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> reverted to Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> in the 50 wt% TMG aq. in the presence of NaCl.<fig id="Fig3"><label>Figure 3</label><caption><p>Ratio of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> and the substituted compounds after dissolution in 50 wt% TMG aq. or equimolar DMSO aq., followed by NaCl addition. *The peak of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> on day 3 in DMSO aq. was observed in only one of the three samples.</p></caption><graphic xlink:href="41598_2021_89144_Fig3_HTML" id="MO3"/></fig></p><p id="Par13">For comparison, the same experiments were performed using a DMSO aq. Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> and [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> were not detected, and only [Pt(NH<sub>3</sub>)Cl(DMSO)]<sup>+</sup> (&#x02212;&#x02009;3160&#x000a0;ppm)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup> was detected on day 1. This trend was retained even after the addition of NaCl. A small amount of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (&#x02212;&#x02009;2115&#x000a0;ppm) was observed on day 3. This indicated that [Pt(NH<sub>3</sub>)Cl(DMSO)]<sup>+</sup> was possible to revert to Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, but Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> was detected only once during experiments performed in triplicate. It was confirmed that [Pt(NH<sub>3</sub>)Cl(DMSO)]<sup>+</sup> in the DMSO aq. scarcely reverted to Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> in the presence of NaCl, unlike [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup>. Based on these results, although ligand exchange of&#x000a0;Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> occurred in both the TMG aq. and DMSO (aq.), the replacing ligand species differed, which resulted in varying anticancer activities that were retained in the TMG aq. but not in DMSO.</p><p id="Par14">The 50 wt% TMG aq. dissolved cisplatin at high concentrations and the resulting solution retained the anticancer effect of cisplatin. Herein, we proposed powderisation, as powders can be conveniently stored and transported. Furthermore, cisplatin is often used as a mixture with other drugs, and cisplatin aqueous solutions are undesirable as they dilute the other drugs. The 50 wt% TMG aq. containing 10&#x000a0;mM cisplatin was freeze-dried. The obtained powder was pale yellow, based on the colour of cisplatin. We regenerated 10&#x000a0;mM cisplatin-containing 50 wt% TMG aq. by adding the same amount of water to the powder to determine the anticancer effect. Then, the regenerated solution was added to MDA-MB-231 cells at final concentrations ranging between 0.1 and 100&#x000a0;&#x000b5;M. The regenerated cisplatin solution killed MDA-MB-231 cells in a dose-dependent manner (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), indicating that freeze-drying did not affect the anticancer effect.<fig id="Fig4"><label>Figure 4</label><caption><p>MDA-MB-231 cell viability after treatment with cisplatin dissolved in 50 wt% TMG aq., with or without powderisation. (n&#x02009;=&#x02009;3, biologically triplicated).</p></caption><graphic xlink:href="41598_2021_89144_Fig4_HTML" id="MO4"/></fig></p><p id="Par15">On dissolving the cisplatin/TMG powder, the powder was rapidly solubilised in water (Fig. <xref rid="MOESM1" ref-type="media">S3</xref>). It requires only 60&#x000a0;s for dissolution whereas the typical dissolution of native cisplatin powder in 50 wt% TMG aq. required approximately 1&#x000a0;h. Therefore, the freeze-dried cisplatin/TMG powder is ready-to-use. Freeze-drying is considered an effective method for preparing rapidly soluble agents because resulting materials often have different crystallinities<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. This could be a critical factor for rapid dissolution and TMG additionally might interfere the crystallisation of cisplatin. For hepatic arterial infusion, cisplatin-saturated PBS (0.15&#x000a0;wt%) is considered the state-of-the-art solution and needs to be heated at 50&#x000a0;&#x000b0;C to dissolve cisplatin. Conversely, the mixed powder was rapidly soluble at room temperature and could prepare an 11-fold concentrated cisplatin solution; the cisplatin/TMG powder is extremely promising for not only fundamental research but also clinical applications, including hepatic arterial infusion. Notably, TMG reportedly reduces nephrotoxicity when cisplatin is administered to mice<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>, and this effect could also be expected with the TMG aq.</p><p id="Par16">In conclusion, the 50 wt% TMG aq. dissolved poorly water-soluble cisplatin. The solubility in 50 wt% TMG aq. was 1.7 wt%, which was 11 times that observed in water. Although the anticancer effect of cisplatin was abolished in DMSO, it was retained in the 50 wt% TMG aq. Furthermore, <sup>195</sup>Pt NMR revealed that a portion of Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> was converted into [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> in the 50 wt% TMG aq. On the other hand, the addition of NaCl induced ligand exchange from [Pt(NH<sub>3</sub>)<sub>2</sub>Cl(H<sub>2</sub>O)]<sup>+</sup> to Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>. As the medium used in this study contained NaCl, this ligand re-exchange was assumed to occur in the presence of TMG. Moreover, the 50 wt% TMG aq. containing 10&#x000a0;mM cisplatin was freeze-dried. The resulting powder was rapidly solubilised at room temperature; this has not been achieved with conventional cisplatin powders.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Information</title><sec id="Sec3"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="41598_2021_89144_MOESM1_ESM.docx"><caption><p>Supplementary Information</p></caption></media></supplementary-material></p></sec></sec></body><back><fn-group><fn><p><bold>Publisher's note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-021-89144-0.</p></sec><ack><title>Acknowledgements</title><p>We thank Ms. S. Yamagishi (Hirata Laboratory) for her technical assistance. This study was partly supported by ACT-X (for K.K., JPMJAX1915 from Japan Science and Technology Agency), KAKENHI (18K14281 for K.K. and 17K07181 for E.H. from the Japan Society for the Promotion of Science), the Leading Initiative for Excellent Young Researchers (for K.K., from Ministry of Education, Culture, Sports, Science and Technology-Japan), and Kanazawa University SAKIGAKE project 2020.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>R.K. and K.I. performed and analysed most of the biological experiments.; R.K. and T.F. performed NMR experiments; G.S. calculated the polarity of TMG; K.K., R.K., K.N., K.T. and E.H. cowrote the manuscript with input from all authors. All authors commented on the final manuscript and contributed to the interpretation of the results.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par17">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yancey</surname><given-names>PH</given-names></name><name><surname>Burg</surname><given-names>MB</given-names></name></person-group><article-title>Counteracting effects of urea and betaine in mammalian cells in culture</article-title><source>Am. J. Physiol. Regul. Integr. Comp. Physiol.</source><year>1990</year><volume>258</volume><fpage>R198</fpage><lpage>R204</lpage></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>DE</given-names></name><name><surname>Noll</surname><given-names>D</given-names></name><name><surname>Roberts</surname><given-names>M</given-names></name><name><surname>Menaia</surname><given-names>J</given-names></name><name><surname>Boone</surname><given-names>D</given-names></name></person-group><article-title>Detection of the osmoregulator betaine in methanogens</article-title><source>Appl. Environ. Microbiol.</source><year>1990</year><volume>56</volume><fpage>563</fpage><lpage>565</lpage><pub-id pub-id-type="pmid">2306094</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cayley</surname><given-names>S</given-names></name><name><surname>Record</surname><given-names>MT</given-names></name></person-group><article-title>Roles of cytoplasmic osmolytes, water, and crowding in the response of <italic>Escherichia coli</italic> to osmotic stress: biophysical basis of osmoprotection by glycine betaine</article-title><source>Biochemistry</source><year>2003</year><volume>42</volume><fpage>12596</fpage><lpage>12609</lpage><pub-id pub-id-type="pmid">14580206</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henke</surname><given-names>W</given-names></name><name><surname>Herdel</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>K</given-names></name><name><surname>Schnorr</surname><given-names>D</given-names></name><name><surname>Loening</surname><given-names>SA</given-names></name></person-group><article-title>Betaine improves the PCR amplification of GC-rich DNA sequences</article-title><source>Nucl. Acids Res.</source><year>1997</year><volume>25</volume><fpage>3957</fpage><lpage>3958</lpage><pub-id pub-id-type="pmid">9380524</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Natural zwitterionic betaine enables cells to survive ultrarapid cryopreservation</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>37458</fpage><pub-id pub-id-type="pmid">27874036</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Mattos</surname><given-names>SF</given-names></name><name><surname>Villalonga</surname><given-names>P</given-names></name><name><surname>Clardy</surname><given-names>J</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name></person-group><article-title>FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><fpage>3237</fpage><lpage>3246</lpage><pub-id pub-id-type="pmid">18852127</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eberle</surname><given-names>KE</given-names></name><name><surname>Sansing</surname><given-names>HA</given-names></name><name><surname>Szaniszlo</surname><given-names>P</given-names></name><name><surname>Resto</surname><given-names>VA</given-names></name><name><surname>Berrier</surname><given-names>AL</given-names></name></person-group><article-title>Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><fpage>e21496</fpage><pub-id pub-id-type="pmid">21720550</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Shen</surname><given-names>M-R</given-names></name><name><surname>Chen</surname><given-names>Y-J</given-names></name><name><surname>Maa</surname><given-names>M-C</given-names></name><name><surname>Leu</surname><given-names>T-H</given-names></name></person-group><article-title>Eps8 decreases chemosensitivity and affects survival of cervical cancer patients</article-title><source>Mol. Cancer Ther.</source><year>2008</year><volume>7</volume><fpage>1376</fpage><lpage>1385</lpage><pub-id pub-id-type="pmid">18566210</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Augustine-Rauch</surname><given-names>KA</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Kleinman</surname><given-names>M</given-names></name><name><surname>Lawton</surname><given-names>R</given-names></name><name><surname>Welsh</surname><given-names>MJ</given-names></name></person-group><article-title>A study of vehicles for dosing rodent whole embryo culture with non aqueous soluble compounds</article-title><source>Reprod. Toxicol.</source><year>2004</year><volume>18</volume><fpage>391</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">15082074</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>MD</given-names></name><etal/></person-group><article-title>Say no to DMSO: dimethylsulfoxide inactivates cisplatin, carboplatin, and other platinum complexes</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>3913</fpage><lpage>3922</lpage><pub-id pub-id-type="pmid">24812268</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheijen</surname><given-names>M</given-names></name><etal/></person-group><article-title>DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro</article-title><source>Sci. Rep.</source><year>2019</year><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">30626917</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>M-H</given-names></name><etal/></person-group><article-title>The cytotoxic effects of dimethyl sulfoxide in mouse preimplantation embryos: a mechanistic study</article-title><source>Theranostics</source><year>2017</year><volume>7</volume><fpage>4735</fpage><pub-id pub-id-type="pmid">29187900</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tun&#x000e7;er</surname><given-names>S</given-names></name><etal/></person-group><article-title>Low dose dimethyl sulfoxide driven gross molecular changes have the potential to interfere with various cellular processes</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><fpage>14828</fpage><pub-id pub-id-type="pmid">30287873</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thaler</surname><given-names>R</given-names></name><name><surname>Spitzer</surname><given-names>S</given-names></name><name><surname>Karlic</surname><given-names>H</given-names></name><name><surname>Klaushofer</surname><given-names>K</given-names></name><name><surname>Varga</surname><given-names>F</given-names></name></person-group><article-title>DMSO is a strong inducer of DNA hydroxymethylation in pre-osteoblastic MC3T3-E1 cells</article-title><source>Epigenetics</source><year>2012</year><volume>7</volume><fpage>635</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">22507896</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerrison</surname><given-names>SJS</given-names></name><name><surname>Sadler</surname><given-names>PJ</given-names></name></person-group><article-title>Solvolysis of cis-[Pt(NH<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>] in dimethyl sulphoxide and reactions of glycine with [PtCl<sub>3</sub>(Me<sub>2</sub>SO)]&#x02013;as probed by <sup>195</sup>Pt nuclear magnetic resonance shifts and <sup>195</sup>Pt&#x02013;<sup>15</sup>N coupling constants</article-title><source>J. Chem. Soc. Chem. Commun.</source><year>1977</year><volume>23</volume><fpage>861</fpage><lpage>863</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>J</given-names></name><etal/></person-group><article-title>Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes</article-title><source>Int. J. Pharm.</source><year>2008</year><volume>349</volume><fpage>38</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17728083</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>JS</given-names></name><name><surname>Liotta</surname><given-names>CL</given-names></name><name><surname>Eckert</surname><given-names>CA</given-names></name></person-group><article-title>Polarity and hydrogen-bonding of ambient to near-critical water: Kamlet&#x02013;Taft solvent parameters</article-title><source>Chem. Commun.</source><year>2001</year><volume>7</volume><fpage>665</fpage><lpage>666</lpage></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satria</surname><given-names>H</given-names></name><name><surname>Kuroda</surname><given-names>K</given-names></name><name><surname>Tsuge</surname><given-names>Y</given-names></name><name><surname>Ninomiya</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name></person-group><article-title>Dimethyl sulfoxide enhances both the cellulose dissolution ability and biocompatibility of a carboxylate-type liquid zwitterion</article-title><source>New J. Chem.</source><year>2018</year><volume>42</volume><fpage>13225</fpage><lpage>13228</lpage></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freeman</surname><given-names>W</given-names></name><name><surname>Pregosin</surname><given-names>PS</given-names></name><name><surname>Sze</surname><given-names>SN</given-names></name><name><surname>Venanzi</surname><given-names>LM</given-names></name></person-group><article-title>Platinum-195NMR using Fourier transform techniques. The PtCl42&#x02212;ion</article-title><source>J. Magn. Reson.</source><year>1976</year><volume>22</volume><fpage>473</fpage><lpage>478</lpage></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>P</given-names></name><name><surname>Koch</surname><given-names>KR</given-names></name></person-group><article-title>A <sup>195</sup>Pt NMR study of the oxidation of [PtCl<sub>4</sub>] 2&#x02212; with chlorate, bromate, and hydrogen peroxide in acidic aqueous solution</article-title><source>J. Coord. Chem.</source><year>2010</year><volume>63</volume><fpage>2561</fpage><lpage>2577</lpage></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bancroft</surname><given-names>DP</given-names></name><name><surname>Lepre</surname><given-names>CA</given-names></name><name><surname>Lippard</surname><given-names>SJ</given-names></name></person-group><article-title>Platinum-<sup>195</sup>NMR kinetic and mechanistic studies of <italic>cis</italic>- and <italic>trans</italic>-diamminedichloroplatinum (II) binding to DNA</article-title><source>J. Am. Chem. Soc.</source><year>1990</year><volume>112</volume><fpage>6860</fpage><lpage>6871</lpage></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Appleton</surname><given-names>TG</given-names></name><name><surname>Hall</surname><given-names>JR</given-names></name><name><surname>Ralph</surname><given-names>S</given-names></name></person-group><article-title><sup>15</sup>N and <sup>195</sup>Pt NMR spectra of platinum ammine complexes: <italic>trans</italic>- and <italic>cis</italic>-influence series based on <sup>195</sup>Pt-<sup>15</sup>N coupling constants and <sup>15</sup>N chemical shifts</article-title><source>Inorg. Chem.</source><year>1985</year><volume>24</volume><fpage>4685</fpage><lpage>4693</lpage></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levason</surname><given-names>W</given-names></name><name><surname>Pletcher</surname><given-names>D</given-names></name></person-group><article-title>195-Platinum nuclear magnetic resonance spectroscopy</article-title><source>Platin. Met. Rev.</source><year>1993</year><volume>37</volume><fpage>17</fpage><lpage>23</lpage></element-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Berg, J. M. Tymoczko, J. L., Stryer, <italic>Biochemistry</italic> (5th ed. Freeman, W. H.) (New York, 2002).</mixed-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>AL</given-names></name><name><surname>Lippard</surname><given-names>SJ</given-names></name></person-group><article-title>Binding of the antitumor drug <italic>cis</italic>-diamminedichloroplatinum (II)(cisplatin) to DNA</article-title><source>Acta Rev. Cancer</source><year>1985</year><volume>780</volume><fpage>167</fpage><lpage>180</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KW</given-names></name><name><surname>Martin</surname><given-names>DS</given-names><suffix>Jr</suffix></name></person-group><article-title>Cis-dichlorodiammineplatinum (II). Aquation equilibria and isotopic exchange of chloride ligands with free chloride and tetrachloroplatinate (II)</article-title><source>Inorg. Chim. Acta</source><year>1976</year><volume>17</volume><fpage>105</fpage><lpage>110</lpage></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L</given-names></name></person-group><article-title>Amorphous pharmaceutical solids: preparation, characterization and stabilization</article-title><source>Adv. Drug Deliv. Rev.</source><year>2001</year><volume>48</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">11325475</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hagar</surname><given-names>H</given-names></name><name><surname>El Medany</surname><given-names>A</given-names></name><name><surname>Salam</surname><given-names>R</given-names></name><name><surname>El Medany</surname><given-names>G</given-names></name><name><surname>Nayal</surname><given-names>OA</given-names></name></person-group><article-title>Betaine supplementation mitigates cisplatin-induced nephrotoxicity by abrogation of oxidative/nitrosative stress and suppression of inflammation and apoptosis in rats</article-title><source>Exp. Toxicol. Pathol.</source><year>2015</year><volume>67</volume><fpage>133</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">25488130</pub-id></element-citation></ref></ref-list></back></article>